Autophagy/Apoptosis Balance in Placental Vascular Pathologies

Summary

Pregnancy increases the risk of thrombosis. Placenta-mediated diseases are a risk factor for cardiovascular pathologies and can lead to maternal-fetal morbidity and mortality. It is essential to understand the cellular and molecular mechanisms of dysfunctions at the vascular-placental interface so that systemic vascular risk can be characterized and, ultimately, screened for, on the basis of new markers (targeted preventive management).

Deregulated autophagy could be the starting point for cell death by apoptosis or necrosis leading to complications.

The pathophysiological mechanisms involved in trophoblast apoptosis are incompletely described. This project follows on from the GrossAuTop-1 study, which investigated the intra- and inter-individual variability of autophagy and apoptosis activities in women during pregnancy. The aim of this project is to study autophagy and apoptosis activities specifically in women developing a placental vascular complication during pregnancy.

Conditions

• Pregnancy Complications
• Pre-Eclampsia
• Growth Retardation, Intrauterine

Interventions

DIAGNOSTIC_TEST

Blood test

16 blood samples (16 tubes, i.e. 55.3 ml) will be taken at inclusion. Pregnant women will be seen every month as part of their pregnancy follow-up, and blood (11 tubes, i.e. 35.5 ml) and urine samples will be taken at each follow-up visit. At delivery, a systematic blood sample will be taken as part of the usual care, and an additional 11 tubes of blood (35.5 ml) will be taken.

DIAGNOSTIC_TEST

Urine test

Urine samples will be taken at the inclusion visit and at each follow-up visit.

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes

  lead OTHER

Principal Investigators

• Marie PORTES, Dr. · Centre Hospitalier Universitaire de Nīmes

• Mathieu FORTIER, Dr. · Centre Hospitalier Universitaire de Nīmes

• Jean-Christophe GRIS, Pr. · Centre Hospitalier Universitaire de Nīmes

• Eve MOUSTY, Dr. · Centre Hospitalier Universitaire de Nīmes

• Vincent LETOUZEY, Dr. · Centre Hospitalier Universitaire de Nīmes

• Stéphanie HUBERLANT, Dr. · Centre Hospitalier Universitaire de Nīmes

• Chloé BOURGUIGNON, Dr. · Centre Hospitalier Universitaire de Nīmes

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-05-02

Primary Completion

2028-05-01

Completion

2029-05-01

Countries

• France

Study Locations